FDA approves new TB drug

FDA says the new drug, Sirturo, was granted fast-track approval through a priority review
Comment E-mail Print Share
First Published: Tue, Jan 01 2013. 12 10 PM IST
Prevalence of the disease in India is more severe, and the new drug may prove most useful in developing countries including India, though the price and availability of the drug maybe a challenge. Photo: Pradeep Gaur/Mint
Prevalence of the disease in India is more severe, and the new drug may prove most useful in developing countries including India, though the price and availability of the drug maybe a challenge. Photo: Pradeep Gaur/Mint
Updated: Wed, Jan 02 2013. 12 02 AM IST
Mumbai: The US Food and Drug Administration (FDA) has approved the first drug for multi-drug resistant tuberculosis (TB), the decade’s most dreaded disease and one without any effective treatment until now.
The new drug, Sirturo, developed by US drug maker and researcher Janssen Therapeutics Inc., was granted fast-track approval through a priority review, FDA said in a statement on Monday.
Multi-drug resistant TB is a result of bacteria developing resistance to the traditional antibiotics used to cure regular TB, leaving patients suffering from the disease without an effective therapeutic option.
Nearly nine million people around the world and 10,528 people in the US were affected with TB in 2011, according to the Centers for Disease Control and Prevention, a US public health agency.
Prevalence of the disease in India is more severe, and the new drug may prove most useful in developing countries including India, though the price and availability of the drug maybe a challenge.
Comment E-mail Print Share
First Published: Tue, Jan 01 2013. 12 10 PM IST
More Topics: FDA | tuberculosis | drug | sirturo | india |
blog comments powered by Disqus
  • Wed, Nov 19 2014. 04 58 PM
  • Wed, Nov 12 2014. 05 13 PM
Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved